Barinthus Biotherapeutics’ (BRNS) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Barinthus Biotherapeutics (NASDAQ:BRNS) in a research report released on Friday morning,Benzinga reports. HC Wainwright currently has a $5.00 target price on the stock.

Separately, Alliance Global Partners cut their target price on Barinthus Biotherapeutics from $11.00 to $9.50 and set a “buy” rating on the stock in a research note on Tuesday, August 13th.

Barinthus Biotherapeutics Price Performance

Shares of Barinthus Biotherapeutics stock opened at $1.37 on Friday. Barinthus Biotherapeutics has a one year low of $1.11 and a one year high of $4.16. The firm has a market capitalization of $55.25 million, a price-to-earnings ratio of -0.91 and a beta of -0.59. The business has a 50-day simple moving average of $1.29 and a 200 day simple moving average of $1.56.

Barinthus Biotherapeutics (NASDAQ:BRNS) last issued its earnings results on Wednesday, November 6th. The company reported ($0.21) EPS for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.23. The firm had revenue of $14.97 million during the quarter. During the same period last year, the firm earned ($0.37) earnings per share. On average, sell-side analysts expect that Barinthus Biotherapeutics will post -1.63 EPS for the current year.

Institutional Investors Weigh In On Barinthus Biotherapeutics

Several institutional investors have recently made changes to their positions in the stock. M&G Plc purchased a new stake in shares of Barinthus Biotherapeutics during the second quarter worth $7,276,000. Alphabet Inc. purchased a new stake in shares of Barinthus Biotherapeutics in the second quarter worth $2,119,000. DC Funds LP purchased a new stake in shares of Barinthus Biotherapeutics in the first quarter worth $1,528,000. BlueCrest Capital Management Ltd purchased a new stake in shares of Barinthus Biotherapeutics in the first quarter worth $1,292,000. Finally, Ipswich Investment Management Co. Inc. purchased a new stake in shares of Barinthus Biotherapeutics in the second quarter worth $32,000. Hedge funds and other institutional investors own 25.20% of the company’s stock.

Barinthus Biotherapeutics Company Profile

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.